olanzapine + clozapine

Olanzapine + clozapine is a combination of two atypical antipsychotic drugs used off-label in the management of treatment-resistant schizophrenia. Both agents act primarily as antagonists at dopamine D2 and serotonin 5-HT2A receptors, but each has a unique receptor binding profile that may provide complementary effects when used together. Clozapine is considered the gold standard for treatment-resistant schizophrenia due to its superior efficacy, particularly for negative symptoms, but its use can be limited by side effects such as agranulocytosis and metabolic disturbances. Olanzapine shares similar efficacy with clozapine but generally has a more favorable hematological safety profile. The combination is sometimes employed in patients who are partial responders or nonresponders to clozapine monotherapy or cannot tolerate higher doses of clozapine alone[1][5]. Evidence supporting this strategy remains limited to case reports and small studies; controlled trials are lacking[1][5]. The main mechanism involves broad antagonism at dopaminergic (D2) and serotonergic (5-HT2A) receptors, with additional activity at histaminergic, muscarinic cholinergic, and adrenergic receptors.

Other names

olanzapine and clozapine combinationclozapine plus olanzapine